Would you use the MIPSS-PV risk scoring to decide in decision making for cytoreductive therapy in PV?

I think the MIPSS-PV is helpful in understanding predicted overall survival and appreciating the risk of progression, the decision to cytoreduce is still routed in the classic thrombosis risk model of age plus thrombosis history.

I would certainly recommend getting an NGS panel to better understand ...